Atrial fibrillation in patients with diabetes: molecular mechanisms and therapeutic perspectives
about
Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan.Role of CHA2DS2-VASc score in predicting new-onset atrial fibrillation in patients with type 2 diabetes mellitus with and without hyperosmolar hyperglycaemic state: real-world data from a nationwide cohort.
P2860
Atrial fibrillation in patients with diabetes: molecular mechanisms and therapeutic perspectives
description
2015 nî lūn-bûn
@nan
2015 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Atrial fibrillation in patient ...... s and therapeutic perspectives
@ast
Atrial fibrillation in patient ...... s and therapeutic perspectives
@en
Atrial fibrillation in patient ...... s and therapeutic perspectives
@nl
type
label
Atrial fibrillation in patient ...... s and therapeutic perspectives
@ast
Atrial fibrillation in patient ...... s and therapeutic perspectives
@en
Atrial fibrillation in patient ...... s and therapeutic perspectives
@nl
prefLabel
Atrial fibrillation in patient ...... s and therapeutic perspectives
@ast
Atrial fibrillation in patient ...... s and therapeutic perspectives
@en
Atrial fibrillation in patient ...... s and therapeutic perspectives
@nl
P2093
P2860
P1476
Atrial fibrillation in patient ...... s and therapeutic perspectives
@en
P2093
Alberto Cresti
Francesco De Sensi
Silva Severi
Tom De Potter
P2860
P304
P356
10.3978/J.ISSN.2223-3652.2015.06.03
P407
P577
2015-10-01T00:00:00Z